Cue Biopharma is trading at $24.99, up 7.81%, supported primarily by biotech-sector strength.
- Shares rebounded after falling from $34.20 on August 14 to $23.18 on August 24.
- XBI rose 2.06% during regular trading, while broader risk-on sentiment also supported equities.
- A shareholder investigation announced August 24 alleges possible fiduciary-duty breaches but does not explain today’s gain; no new company-specific catalyst was identified for August 25.